COVID-19 genomic surveillance

COVID-19 genomic surveillance

What is the current capacity for next-generation sequencing of SARS-CoV-2 globally? Where do we need to focus capacity building efforts in order to improve coverage of SARS-CoV-2 genomic data in LMICs?

FIND has carried out a systematic mapping of existing global capacity for SARS-CoV-2 genomic surveillance and developed a framework to classify countries into different archetypes based on diagnostic testing capacity, NGS capacity and ongoing in-country SARS‑CoV‑2 sequencing. The capacity mapping data can be visualized through an interactive dashboard, built in partnership with The Rockefeller Foundation. Read more on the capacity mapping methodology and proposed country classification framework HERE.

The interactive NGS capacity map can also be accessed directly via the dashboard below.

Click HERE to view in full screen.

How are LMICs being supported in their efforts to enhance sequencing capacity for COVID-19 genomic surveillance? To answer this, FIND gathered input from Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar partners to assess the extent of partner support being provided globally.

How have sequencing technologies been used to understand and mitigate the ongoing COVID-19 pandemic?

Read our comprehensive sequencing landscape developed with the PHG Foundation. The first version of this report was completed in June 2020; an information update was carried out in February and March 2021, with an emphasis on global genomic surveillance.

What do we know about the impact of SARS-CoV-2 variants of concern on diagnostic tests, vaccines, and public health measures? How can genomic surveillance support in identifying and managing the impact of these variants?

Read our new report developed with the PHG Foundation.

Page last updated 13 Apr 2022

Quick links